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Topical retinoids inhibit matrix metalloproteinases and accelerate collagen synthesis, thereby triggering antiaging eﬀects in the
skin. However, topical retinoids can cause severe skin reactions, including scaling, erythema, papules, and inﬂammation. The
presentstudydemonstratesthattheethanolicbarkextractofAlstoniascholarisR.Br.cansigniﬁcantlyinhibitall-transretinoicacid-
induced inﬂammation in human HaCat keratinocyte cells. Furthermore, two representative retinoid-induced proinﬂammatory
cytokines, monocyte chemoattractant protein-1 and interleukin-8, were signiﬁcantly suppressed by A. scholaris extract (by
82.1% and 26.3% at 100ppm, and dose-dependently across the tested concentrations) in vitro. In a cumulative irritation patch
test, A. scholaris extract decreased retinol-induced skin irritation, while strengthening the ability of retinoids to inhibit matrix
metalloproteinase-1expression,whichisstronglyassociatedwithagingeﬀects.TheseresultssuggestthatA.scholarisisapromising
compound that may increase the antiaging function of retinoids while reducing their ability to cause skin irritation.
1.Introduction
Skin,whichisthelargestorganofthehumanbody,functions
as a physical, biological, and physiological barrier. These
functions can be impaired by external and internal factors,
such as ultraviolet (UV) light, xenobiotics, and hormonal
changes [1–3]. These factors trigger various signs of skin
aging, which is commonly characterized by the formation of
ﬁne wrinkles, reduced water content, and decreased skin
thickness [2]. Wrinkling or photodamaging of the upper
dermis is closely associated with disorganization of col-
lagen/elastin-based connective tissues [4], while wrinkles
are formed by degradation of the extracellular matrix via
changes in matrix metalloproteinase (MMP) levels [5, 6].
The involved MMPs include several members of the zinc
endopeptidase family: collagenase-1 (MMP-1), stromelysin
(MMP-3), and 92-kDa gelatinase (MMP-9) [7, 8].
The topical application of retinoids relieves skin wrinkles
caused either by natural aging [2] or photoaging [7, 9–11].
Furthermore, retinoids are widely used as topical treatments
for various conditions, such as acne and psoriasis, and in
dermatology clinics for skin cancer therapy [9, 12, 13].
Topical retinoids inhibit the UV-induced, MMP-mediated
breakdown of collagen [8] and protect against UV-induced
decreases in procollagen expression [14]. However, topical
retinoidtherapyisfrequentlyaccompaniedbyinﬂammation;
this is commonly known as “retinoid dermatitis” [15–17].
Currently, scientists are seeking to overcome the problem
of retinoid dermatitis. Some approaches using novel ingre-
dients have been proposed, but it would be very useful to
develop anti-irritants capable of reducing the disadvantages
of topical retinoid therapy.
In certain individuals, they experience more intense and
frequent adverse sensory eﬀects than the normal population
after topical use of personal care products, a phenomenon
knowninpopularusageassensitiveskin[18].Arecentreport
showed that approximately 40% of people consider them-
selves to possess the characteristics of sensitive skin [19],2 Evidence-Based Complementary and Alternative Medicine
which represents as a skin type showing higher reactivity
thannormalskinanddevelopingexaggeratedreactionswhen
exposedtoexternalfactors[20].Itisacomplexproblemwith
genetic,
Primary ﬁbroblasts were seeded in a 2-well plate (3.0 ×
104 cells/well) and grown for 24h. The resulting monolayers
were washed three times with 2mL of PBS, and then 2mL
of serum-free/phenol red-free DMEM was added to each
well. After 24h, the serum-starved cells were washed three
times with PBS and exposed to UVB irradiation (UVB
lamp, G15TBE, Sankyo Denki, Japan); the total energy dose
of UVB irradiation was 40mJ/cm2.A f t e rU V Be x p o s u r e ,
serum-free DMEM containing the indicated concentrations
of ATRA, ROL, ASE, ATRA/ASE, or ROL/ASE was added
to the cells and incubation was continued for an additional
24h. Supernatants were collected and subjected to MMP-1-
speciﬁc sandwich ELISA (RPN 2610, Amersham Bioscience,
Buckinghamshire, UK) according to the manufacturer’s pro-
tocols,usingprecoated96-wellimmunoplates,rabbitantihu-
man MMP-1 antibodies, horseradish-peroxidase-conjugated
antirabbit IgG, and 3,3 ,5,5 -tetramethyl benzidine (TMB,
used as a peroxidase substrate; Sigma-Aldrich). Absorbance
was read at 450nm using a SoftMax Pro 5.0 (Molecular
Devices).
All samples were tested in triplicate and the proteins
amounts were expressed in ng/mL. The inhibition % of
MMP-1 expression was calculated by following formula:
Inhibition % of MMP-1 expression = (MMP-1 protein level
in the UVB-irradiated group – MMP-1 protein level in the
test-material-treated group)/(MMP-1 protein level in the
UVB-irradiated group − MMP-1 protein level in the non-
treated control group) × 100. The experimental data were
expressed as averages ± SD and signiﬁcance was analyzed
using the two-sample t-test (Minitab 14.0), with P<0.05
considered statistically signiﬁcant.
1.1. Neuronal Cell Culture and Calcitonin Gene-Related
P e p t i d e( C G R P )A s s a y.Human SK-N-BE(2) and SH-SY5Y
neuroblastoma cells (American Type Culture Collection,
Manassas, Va, USA) were grown in DMEM supplemented
with 2mM/L L-glutamine, 10% heat-inactivated FBS, and
1% penicillin/Streptomycin (Invitrogen, Carlsbad, Calif,
USA). To induce diﬀerentiation, cells were seeded on 12-well
plates(5.0×104 cells/well)inserum-containingmediumand
then stimulated for 2 weeks with 10μMA T R A ,1 0μMA T R A
plus 1ppm ASE, or 10μM ATRA plus 10ppm ASE. The
medium was replaced every 2-3 days. The diﬀerentiated SK-
N-BE(2) and SH-SY5Y cells were then incubated in serum-
free DMEM containing 300nM capsaicin for 4h, and the
levels of CGRP in the conditioned media were determined
by ELISA (E0876h; USCNLIFE, Missouri, Tex, USA).
1.2. Anti-Inﬂammatory Eﬀect on ROL-Induced Irritation in
Human Skins. To evaluate the potential ability of ASE to
decrease ROL-induced irritation in human skin, a modiﬁed
cumulative irritation (mCI) test was performed. An oil-
in-water (O/W) emulsion was prepared by homogenizing
a 13.9wt% oil mixture in water at 7.0 × 103 rpm for 5min
at 70◦C. The utilized oil mixture consisted of 6.5% cetearyl
alcohol/cetearylglucoside(MONTANOV68,Seppic,France),
3.6%glycerylstearate/PEG-100stearate(ARLACEL165VEG;
Croda, Edison, NJ, USA), 3.6% glyceryl stearate, 7.2% ce-
tearyl alcohol, 21.6% squalane, 21.6% cetyl ethylhexanoate,
and 36% decamethyl cyclopentasiloxane. The viscosities of
the emulsions were adjusted to ∼4.0 × 104 cps by tuning the
concentration of CARBOPOL ETD 2020 polymer (Lubrizol
Advanced Materials, Cleveland, Ohio, USA). A stabilized
retinol system was used to encapsulate the retinol (0.075%,
2500 international units (IU)) in polymer particles, which
werethenhomogeneously dispersed in the emulsionat room
temperature [27].
individual, environmental, occupational, and ethnic im-
plications, and subjective symptoms of sensitive skin include
erythema, itching, burning, and stinging [20, 21], which
are often closely related to abnormal skin barrier function
and/or accelerated nerve responses. Peripheral activation
of certain aﬀerent sensory neurons has been shown to pro-
duce various inﬂammatory responses. Cutaneous nerve ﬁ-
bers are important regulators in this process, which is called
“neurogenic inﬂammation” [22]. They contain proinﬂam-
matory neuropeptides, such as calcitonin gene-related pep-
tide (CGRP), vasoactive intestinal peptide (VIP), and ta-
chykinin-like substance P (SP) [23]. Among these, CGRP is
a 37-amino acid peptide known to be a major component
released from nerve endings [24].
Folk medicine has a long history of treating diverse dis-
eases, and some herbal folk medicines have been adopted
by the pharmaceutical and cosmetic industries. Here, we
assess the potential use of Alstonia scholaris (L.) R. Br. as a
novel anti-irritant for reducing retinoid-induced dermatitis.
A. scholaris is a tree belonging to the family Apocynaceae; it
is widely distributed in South and Southeast Asia [25]a n d
has traditionally been used to treat asthma, pneumonia, and
fever [26]. Despite this wide use, no prior study that we
are aware of has examined the potential anti-inﬂammatory
or anti-irritative activities of A. scholaris in skin. Here, we
prepared an alcoholic extract from the stem bark of A.
scholaris and investigated its potential anti-inﬂammatory
eﬀects on human skin.
2.MaterialandMethods
2.1. Plant Materials and Extraction. A. scholaris was kindly
supplied by the Institute of Natural Products Chem-
istry (Vietnam). A voucher specimen (KHUP-0107) was
deposited in the Museum of Korean Crude Drugs (Kyung
Hee University, South Korea). Dried stem bark of A. scholaris
(190g) was extracted with 70% ethanol (2L × 3) at room
temperature using a sonicator (3h × 3). The extract was
evaporated to dryness under a vacuum at 40◦C, yielding a
brown residue (31.5g).
2.2. Cell Culture. Human HaCaT keratinocytes were cul-
t u r e di nD u l b e c c o ’ sm o d i ﬁ e dE a g l e ’ sm e d i u m( D M E M ,
Lonza, Basel, Switzerland) supplemented with 10% heat-
inactivated fetal bovine serum (FBS; Gibco, Carlsbad, Calif,
USA) and 100U/mL penicillin/streptomycin (Lonza), at
37◦C in a humidiﬁed atmosphere containing 5% CO2.Evidence-Based Complementary and Alternative Medicine 3
Primary dermal ﬁbroblasts were obtained from human adult
foreskins obtained from healthy volunteers and cultured
in DMEM supplemented with 1% penicillin/streptomycin
and 10% heat-inactivated FBS at 37◦C in a humidiﬁed
atmosphere containing 5% CO2. The cells were cultured to
90% conﬂuence before being passaged; passages 4 to 7 were
used for experiments.
2.3. Cell Viability Assay. Cell viability tests were performed
forculturesexposedtothefollowingagents:all-transretinoic
acid (ATRA; Sigma-Aldrich, St. Louis, Mo, USA), retinol
(ROL; Sigma-Aldrich), ASE (Alstonia scholaris extract), and
mixtures of ATRA/ASE and ROL/ASE.
2.4. In Vitro Assay for Inhibition of ATRA-Induced Inﬂamma-
tion. HaCaT cells were seeded in a 96-well plate (2.0 × 104
cells/well)andgrownfor24h.Theresultingmonolayerswere
washed three times with 200μL of phosphate buﬀered saline
(PBS; Lonza), and then 200μLo fs e r u m - f r e eD M E Mw a s
addedtoeachwell.After24hofserumstarvation,themono-
layers were washed three times with PBS, and 150 μLo f1 %
FBS-containing media was added. Cells were treated with
50 μL of diluted anti-irritants (madecassoside or hydrocor-
tisone) or ASE for 10min, then 50μLo f1μMA T R Ai n1 %
FBS-containing media was added to the anti-irritant-treated
cells, and incubation was continued for another 24h. Super-
natants were collected, and enzyme-linked immunosor-
bent assay (ELISA) was performed against interleukin-8
(IL-8) and monocyte chemoattractant protein-1 (MCP-1)
(BD OptEIATM; BD Biosciences, San Diego, Calif, USA)
according to the manufacturer’s protocol. Each conjugate
was incubated with 2,2 -azino-bis-3-ethylbenzthiazoline-6-
sulfonicacid(Sigma-Aldrich),andabsorbancewasmeasured
at 405nm using a SoftMax Pro 5 (Molecular Devices, Sun-
nyvale, Calif, USA).
All samples were tested in triplicate, and the protein
a m o u n t sw e r ee x p r e s s e di np g / m L .T h er e d u c t i o n%o f
ATRA-induced irritation was calculated using the following
formula: reduction % of irritation = (cytokine protein level
in ATRA-treated group − cytokine protein level in anti-
irritanttreatedgroup)/(cytokineproteinlevelinATRA-treat-
ed group − cytokine protein level in nontreated control
group) × 100. The experimental data were expressed as
averages ± SD, and signiﬁcance was analyzed using the two-
sample t-test (Minitab 14.0; Pennsylvania, Minitab Inc.),
with P<0.05 considered statistically signiﬁcant.
2.5. In Vitro Assay for Inhibition of ATRA-Induced MMP-1
Expression. The resulting creams, one containing 2500 IU
retinol (3.33IU = 1 retinol equivalent (RE) = 1μg of retinol)
with 0.1% ASE (test emulsion) and one containing 2500 IU
retinol alone (control emulsion), were tested on 21 healthy
adults (8 males and 13 females). For the tests, 30μLo fc r e a m
was applied to a 2.5-cm-diameter area of the volar forearm
a n dr u b b e d5 0t i m e s .T h et r e a t e da r e aw a st h e nw r a p p e d
w i t hp l a s t i cw r a pf o r3 h .T h i sp r o c e d u r ew a sp e r f o r m e d
twice each business day for 3 weeks (total 15 days. Every
day prior to the ﬁrst application, the skin reactions were
graded according to a modiﬁed criteria proposed by Frosch
andKligmanin1979[28]andCTFA(Cosmetic,Toiletry,and
Fragrance Association) guidelines of 1981 as follows: 0 = no
reaction; 1 = slight erythema, spotty or diﬀuse; 2 = moderate
uniform erythema; 3 = intense erythema with edema; 4 =
intenseerythemawithedemaandvesicles.Variousotherskin
symptoms (scales, ﬁssures, etc.) were also noted. If a subject
showed skin irritations over grade 3, the topical application
was stopped. However, the skin examinations continued to
the end of test.
Thenumericalscore(cumulativeirritationindex)ofeach
subject was summed, and the mean was compared between
the test emulsion (ROL + 0.1% ASE) and control emulsion
(ROL).Themaximumpossiblescorewas1260(21persons ×
15 days × 4). The irritation index was calculated as follows:
average = sum/number of subjects (n = 21). Test results
were statistically analyzed using the nonparametric Mann
Whitney test (Minitab 14.0), with P values < 0.01 regarded
as signiﬁcant. The formulated emulsions were stored at 4◦C
during the test period. The retinol titer did not signiﬁcantly
diﬀer between day 0 and day 15. This study was approved
by the ethics committee of the DERMAPRO/Skin Research
Center (Seoul, Republic of Korea), and patients gave written
informed consent.
2.6. Human Repeat Insult Patch Test (HRIPT). To evaluate
the sensitization potential of ASE toward human skin, a
repeat insult patch test (RIPT) was performed [29, 30]. We
prepared an oil-in-water (O/W) emulsion by homogenizing
a 18.8wt% oil mixture in water at 7.0 × 103 rpm for 5min
at 70◦C. The oil mixture consisted of 26.6% hydrogenated
polydecene, 26.6% cetyl octanoate, 26.6% limnanthes alba
(meadowfoam) seed oil, 8% polysorbate 60, 5.3% cetearyl
alcohol, 5.3% glyceryl stearate, and 1.6% sorbitan stearate.
The viscosities of the emulsions were adjusted to ∼4.0 ×
104 cps by tuning the concentration of sepiplus 400 (Seppic,
France).
Emulsions (20μL) with or without 0.2% ASE were
applied to the volar forearms of volunteers using IQ cham-
bers (Chemotechnique Diagnostics, Sweden). The patches
were removed after 24h, and skin responses were evaluated
within 1h of patch removal. Three induction patches were
applied each week for a total of 3 weeks. Following a 2-week
rest period (during which no patches were applied), a single
challenge application of the same material was applied to a
na¨ ıve site (another arm) and left on for 48h. Skin responses
were evaluated at 30min, 24h, and 48h after patch removal.
Theskinresponsesobtainedduringtheinductionphasewere
scored according to the modiﬁed criteria proposed by Frosch
and Kligman in 1979 [28] and the CTFA guidelines of 1981
[31]. During the challenge phase, the results were scored
accordingtotheterminologyestablishedbytheInternational
Contact Dermatitis Research Group (ICDRG). Brieﬂy, the
condition of the skin in the treated areas was classiﬁed
as follows: 1 (+) = doubtful reaction consisting of only
faint erythema; 2 (+) = weak positive reaction comprising
erythema, inﬁltration, and possibly papules; 3 (++) = strong
positive reaction comprising erythema, inﬁltration, papules,4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: HPLC chromatogram of the ethanolic extract of A. scholaris.
and vesicles; 4 (+++) = extreme positive reaction comprising
intense erythema and inﬁltration, as well as coalescing
vesicles. Various other skin symptoms (scales, ﬁssures, etc.)
were also noted. Each examination was performed under
standard-light conditions by a qualiﬁed research expert or
a dermatologist. This study was approved by the above-
noted ethics committee, and patients gave written informed
consent.
2.7. HPLC Analysis. Chromatographic measurements were
performed using an HPLC system (Waters, Milford, Mass,
USA) comprising a 515 pump, a 717 autosampler and
a 996 photodiode array detector, and operated by the
Waters Empower software. Chemical ﬁngerprint analysis
was performed using a Shiseido Capcell-pak C18 (Tokyo,
Japan) column (250 ×4.6mm i.d.; 5μm). The UV data were
collected from 200 to 400nm. The mobile phase comprised
methanol (solvent A) and water (solvent B) in a linear
gradient that increased from 5% solvent A to 100% A over
55min. The ﬂow rate was 0.8mL/min, and the injection
volume was 7μL.
2.8. Electrospray Ionization with Time-of-Flight Mass Spec-
trometry (ESI-TOFMS). Mass spectra were measured by
ESI-TOFMS. The ESI ion source (Jeol, Tokyo, Japan) was
coupled to a JMS-T100TD (AccuTOF-TLC, Tokyo, Japan)
in the positive-ion mode with a discharge needle voltage of
2000V and a nebulizing nitrogen gas ﬂow of 1.5L/min. The
ﬁrst oriﬁce lens was set to 100V, and the ring lens was set to
13V. The TOF-MS was set with a peak voltage of 2500V, a
bias voltage of 29V, a pusher bias voltage of −0.76V, and a
detector voltage of 2300V.
3. Result
3.1. HPLC Fingerprint of the A. scholaris Extract (ASE).
To compare our generated ASE with results from previous
papers and establish a standard chromatogram for future
quality control of ASE, a standard HPLC chromatogram
was performed and the results were corroborated across
various column types and mobile phase compositions. A
representative result is shown in Figure 1. Two compounds
previously identiﬁed from this plant were well resolved from
other components in the chromatogram [32, 33]. Their
identities were conﬁrmed by comparing the high-resolution
mass spectra measured from the Accu-TOF analyzer with
calculated values. The experimental mass value of the
echitamine ion was 385.2127 (calc. 385.2086), while that of
the sodiated adduct of the loganin ion was 413.1423 (calc.
413.1396).
3.2. Anti-Inﬂammatory Eﬀects of ASE on ATRA-Induced
Inﬂammation In Vitro . Next, we investigated the potential
anti-inﬂammatory eﬀects of ASE and compared them to
those of two well-known compounds, madecassoside and
hydrocortisone. HaCaT cells were treated with ATRA with
or without the indicated concentrations of the various
agents,andthelevelofproinﬂammatorycytokines,whichare
interleukin-8 (IL-8) and monocyte chemoattractant protein-
1 (MCP-1), was measured in collected supernatants. As
shown in Figure 2 and Table 1, ASE conferred a strong anti-
inﬂammatory eﬀect with ASE-treated cells showing MCP-
1 levels that were 928.8 ± 64.0pg/mL (at 100ppm) and
1074.0 ± 82.2pg/mL (at 500ppm) lower than those in con-
trol cells. This inhibition was less than that seen in madec-
assoside-treatedcells,inwhichtheMCP-1levelsdecreasedbyEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Anti-inﬂammatory eﬀect of A. scholaris extract (ASE) on HaCaT human keratinocytes treated with all-trans retinoic acid (ATRA),
as assessed by monitoring the protein expression of (a) monocyte chemoattractant protein-1 (MCP-1) and (b) interleukin-8 (IL-8). All
results are expressed as average ± SD. ∗P<0.05 and ∗∗P<0.01 compared with the ATRA-treated group.
Table 1: Anti-inﬂammatory eﬀect of Alstonia scholaris extract in all-trans retinoic acid treated HaCaT human keratinocytes.
Test substances
MCP-1 IL-8
pg/mL %o f
inhibition pg/mL %o f
inhibition
ASE 500ppm + ATRA 1μM 928.8 ± 64.0∗∗ 96.6 417.1 ± 29.0∗∗ 83.9
ASE 100ppm + ATRA 1μM 1074.0 ± 82.2∗∗ 82.1 619.3 ± 44.4∗∗ 26.3
Madecassoside 500ppm + ATRA 1uM 1271.0 ± 69.0∗ 62.5 589.8 ± 31.0∗ 34.7
Madecassoside 100ppm + ATRA 1uM 1221.6 ± 100.8∗ 67.4 584.6 ± 70.6∗∗ 36.2
Hydrocortisone 1ppm + ATRA 1μM 1027.6 ± 48.5∗∗ 86.8 407.7 ± 20.8∗ 86.6
ATRA 1 μM 1898.2 ± 72.0 0 711.8 ± 27.0 0
Control 894.7 ± 141.0 100.0 360.4 ± 28.8 100.0
ASE: Alstonia scholaris extract; ATRA: all-trans retinoic acid; MCP-1: monocyte chemoattractant protein-1; IL-8: interleukin-8; Results are expressed as
mean ± SD. ∗P<0.05 and ∗∗P<0.01 compared with ATRA-treated group values.
1221.6±100.8pg/mL(at100ppm)and1271.0 ±69.0pg/mL
(at 500ppm), but it was comparable to that seen in
hydrocortisone-treatedcells(1027.6 ±48.5pg/mLat1ppm).
ASE also signiﬁcantly decreased IL-8 expression by 619.3 ±
44.4pg/mL at 100ppm and 417.1 ± 29.0pg/mL at 500ppm;
these were comparable to the results obtained from made-
cassoside, which decreased IL-8 expression by 584.6 ±
70.6pg/mL at 100ppm and 589.8 ± 31.0pg/mL at 500ppm.
The eﬀective concentrations of ASE were not cytotoxic to
HaCaT cells (data not shown), indicating that the observed
anti-inﬂammatory eﬀects were not associated with cytotoxi-
city.
3.3. Inhibitory Eﬀect of ASE on MMP-1 Production by
Irradiated Human Dermal Fibroblasts. To further examine
the eﬀects of ASE, we examined the production of MMP-16 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀect of ASE associated with UV-induced MMP-1 expression on human primary ﬁbroblasts. (a) Matrix metalloproteinase-1
expression in UVB-irradiated human primary ﬁbroblasts treated with or without ASE. (b) Eﬀect of ATRA or retinol (ROL) plus ASE on
matrix metalloproteinase-1 expression. ∗P<0.05 and ∗∗P<0.01 compared with the UVB-irradiated group.
IOIV-10 Control
(a)
IOIV-10
Control
(b)
IOIV-10 Control
(c)
IOIV-10 Control
(d)
IOIV-10 Control
(e)
Figure 4: The pictures of ﬁve volunteer subjects: eﬀect of ASE on retinol-induced skin irritation in vivo. IOIV-10: test emulsion containing
2500 IU ROL and 0.1% ASE; control: emulsion containing 2500 IU ROL.Evidence-Based Complementary and Alternative Medicine 7
Table 2: Matrix metalloproteinase-1 levels: inhibitory eﬀect of A. scholaris extract in UVB-irradiated human primary ﬁbroblasts. Eﬀect of
all-trans retinoic acid or retinol cotreatment on matrix metalloproteinase-1 expression inhibitory activity of A. scholaris extract in UVB-
irradiated human primary ﬁbroblasts.
(a)
Test conditions ng/mL %o f
inhibition
ASE 0.1ppm + UVB 40mJ 621.8 ± 27.8∗∗ 59.4
ASE 1ppm + UVB 40mJ 451.0 ± 38.4∗∗ 98.8
ASE 10ppm + UVB 40mJ 331.2 ± 22.2∗∗ 126.5
ATRA 1 μM + UVB 40mJ 557.4 ± 9.7∗∗ 74.3
ATRA 5 μM + UVB 40mJ 505.3 ± 64.1∗ 86.3
ROL 1μM + UVB 40mJ 708.9 ± 30.8∗ 39.2
ROL 5μM + UVB 40mJ 574.9 ± 51.1∗ 70.2
UVB 40mJ 878.5 ± 30.2 0
Control 446.0 ± 28.5 100.0
MMP-1: Matrix metalloproteinase-1; ASE: Alstonia scholaris extract; ATRA: all-trans retinoic acid; ROL: retinol. ∗P<0.05 and ∗∗P<0.01 compared
with UVB-irradiated group values.
(b)
Test substance ng/mL %o f
inhibition
ATRA 1 μM + UVB 40mJ 557.4 ± 9.7∗∗ 74.3
ASE 0.1ppm + ATRA 1μM + UVB 40mJ 424.6 ± 6.9∗∗ 105.0
ASE 1ppm + ATRA 1μM + UVB 40mJ 379.7 ± 18.3∗∗ 115.3
ASE 10ppm + ATRA 1μM + UVB 40mJ 335.6 ± 50.5∗∗ 125.5
ROL 1μM + UVB 40mJ 708.9 ± 30.8∗ 39.2
ASE 0.1ppm + ROL 1μM + UVB 40mJ 522.5 ± 13.3∗∗ 82.3
ASE 1ppm + ROL 1μM + UVB 40mJ 439.4 ± 38.4∗∗ 101.5
ASE 10ppm + ROL 1μM + UVB 40mJ 389.3 ± 28.1∗∗ 113.1
UVB 40mJ 878.5 ± 30.2 0.0
Control 446.0 ± 28.5 100.0
MMP-1: Matrix metalloproteinase-1; ASE: Alstonia scholaris extract; ATRA: all-trans retinoic acid; ROL: retinol. ∗P<0.05 and ∗∗P<0.01 compared
with UVB-irradiated group values.
Table 3: Evaluation of capsaicin-induced CGRP expression in the presence or absence of ASE in the SH-SY5Y and SK-N-BE(2)
neuroblastoma cell lines.
Test substance
SH-SY5Y SK-N-BE(2)
pg/mL %o f
inhibition pg/mL %o f
inhibition
Capsaicin 300nM + ASE 1ppm 27.2 ± 2.9∗ 97.7 5.3 ± 1.3 79.0
Capsaicin 300nM + ASE 10ppm 24.6 ± 3.8∗ 104.0 4.6 ± 0.2∗ 108.4
Capsaicin 300nM 66.6 ± 11.9 0 7.2 ± 0.8 0
Control 26.3 ± 2.1 100 4.8 ± 1.2 100
∗P<0.05 compared with capsaicin-treated group values.
by UVB-irradiated human dermal ﬁbroblasts in the pres-
ence and absence of ASE and whether ASE could aﬀect
photoaging. As shown in Table 2(a) and Figure 3(a),U V B -
irradiated human dermal ﬁbroblasts produced 2-fold more
MMP-1 than nonirradiated control cells, but treatment
of these cells with ATRA, ROL, and ASE eﬀectively and
dose-dependently inhibited MMP-1 production. Notably,
cotreatment of cells with ASE/ATRA or ASE/ROL enhanced
the inhibition eﬀect (Table 2(b) and Figure 2(b)). Treatment
with 10ppm ASE plus 1μM ATRA or ROL signiﬁcantly
attenuated MMP-1 expression by 335.6 ± 50.5ng/mL and
389.3 ± 28.1ng/mL, respectively. These values were much
lower than the inhibitions observed in cells treated with
ATRA or ROL alone (557.4 ± 9.7ng/mL for 1μMA T R A ;
708.9 ± 30.8ng/mL for 1μM ROL). This ﬁnding indicates
that the use of ASE appears to have a synergistic eﬀect on8 Evidence-Based Complementary and Alternative Medicine
Table 4: Visual scoring results. Test emulsion contained with 0.1%
ASE with ROL 2500 IU; control: control emulsion with ROL 2500
IU.
Subject 0.1% ASE + ROL 2500 IU Control (ROL 2500 IU)
#1 3 3
#2 4 4
#3 4 5
#4 1 2
#5 0 2
#6 0 0
#7 1 2
#8 0 4
#9 4 12
#10 0 7
#11 1 3
#12 2 3
#13 0 1
#14 6 6
#15 0 17
#16 5 12
#17 5 8
#18 0 10
#19 4 10
#20 1 0
#21 0 1
Sum† 41 112
Mean‡ 1.95∗ 5.33
†means as sum value of the daily irritation scores of all subjects for a test
compound. A maximum score was 1260 (21 persons × 15 days × 4).
‡calculated as follows: mean = sum/n (the number of subjects; n = 21).
∗P < 0.01 was calculated versus control (retinol treated).
the retinoid-induced suppression of MMP-1 expression in
this system.
3.4.TheEﬀectofASEonCapsaicin-InducedCGRPProduction.
To further investigate the eﬀect of ASE on neurogenic
inﬂammation, we assessed the production of CGRP from
diﬀerentiatedneuronalcellstreatedwith300nMofcapsaicin
with or without ASE. The results are summarized in Table 3.
Brieﬂy,CGRPproductionwasincreasedabout150∼250%by
capsaicin treatment, but this increase was dose-dependently
inhibited by cotreatment with ASE. We further observed that
ASE did not aﬀect neurite outgrowth compared with that in
neuronal cells treated with capsaicin alone.
3.5. Anti-Inﬂammatory Eﬀect of ASE on Retinol-Induced Irri-
tation of Human Skin. The anti-irritation potential of ASE
on human skin was evaluated by the cumulative irritation
test using retinol-contained emulsion in the presence and
the absence of ASE. The study population consisted of 21
subjects aged 23 to 36 (mean age of 28.2), and skin irritation
responses were scored. The response tendency of several
subjects are shown in Figure 4. Brieﬂy, the mean irritation
score of the test emulsion was 1.95, whereas that of the
control emulsion (lacking ASE) was 5.33 (Table 4). Thus,
the presence of ASE appeared to signiﬁcantly decrease ROL-
induced skin inﬂammation (by ∼60%; P<0.01).
3.6. In Vivo Sensitization Potential of ASE in Human Skin.
To evaluate the sensitization potential of ASE toward human
skin, HRIPT was carried out on 59 healthy female volunteers
aged 18 to 48 (mean age 34.5); 54 volunteers completed the
test, while ﬁve subjects discontinued for personal reasons.
During the induction phase, 18 volunteers showed skin re-
actions of grade 1 to the test emulsion, nonetheless, they did
not show any certain tendency or speciﬁcity concerned with
cumulative skin irritation. 20 volunteers displayed skin reac-
tions of grade 1 to the control emulsion, but these symptoms
disappeared within 72h and did not show any speciﬁcity.
In the challenge phase, nine subjects who received the test
emulsion showed skin reactions of grade 1+; these skin re-
actions disappeared within 72h among eight of these pa-
tients, while one (#08) showed a skin reaction that was sus-
tained to 96h without any further signs. In order to check
the reproducibility of this result, a second challenge was
performed on subject #08. During the second challenge
phase, this patient did not show any skin response (data
not shown). Among the subjects who received the control
emulsion, eight showed skin reactions of grade 1+, but these
signs disappeared within 72h. These HRIPT results suggest
that ASE could trigger very weak, transient skin responses,
but did not appear to induce allergy-speciﬁc symptoms (e.g.,
edema and itching) or any reproducible skin pathology.
4. Discussion
The phytochemical constituents of Alstonia spp. have been
extensively investigated, with nearly 400 compounds isolated
and characterized to date [25, 34, 35]. In particular, ASE is
known to comprise a variety of alkaloids, ﬂavonoids, and
terpenoids [25, 36, 37]. The constituent alkaloids include
alstonidine,alstonine,chlorogenicacid,chlorogenine,ditain,
echitamine, and echitenin, while the triterpenoids include
lupeol linoleate and lupeol [38–40]. The major alkaloid
obtained from the bark is echitamine, which may be isolated
as a chloride [41]. In the present work, our Accu-TOF
analysis identiﬁed two major compounds from ASE, echita-
mine and loganin (Figure 1), which are well-known for both
their anti-inﬂammatory eﬀects and their cough-relieving
activities [42–44]. Therefore, the anti-inﬂammatory eﬀects
of A. scholaris identiﬁed herein may be due to the actions of
its major components, echitamine and loganin, along with
other compounds, such as ﬂavonoids and terpenes.
We then evaluated the ability of ASE to inhibit retinoid-
induced inﬂammation of the human skin. Retinoid-induced
dermatitis is typically characterized by mild erythema, peel-
ing of the stratum corneum, and manifestation of vari-
ous other symptoms that are mediated by inﬂammatory
cytokines, such as monocyte chemoattractant protein-1
(MCP-1) and interleukin-8 (IL-8) [45]. Our results revealed
that ASE dose-dependently down-regulated the ATRA-
induced releases of MCP-1 and IL-8 from HaCaT human ke-
ratinocytes, indicating that the extract can dramaticallyEvidence-Based Complementary and Alternative Medicine 9
inhibit the ATRA-induced secretion of inﬂammatory cytok-
ines (Figure 2). The inhibitory eﬀects of ASE were higher
than that of madecassoside at 500ppm, a well-known natu-
ral anti-inﬂammatory compound whose major active com-
pound is the pentacyclic triterpenoid saponin isolated from
Centella asiatica [46–48].
Increases in MMP-1 activity have been strongly corre-
lated with aging [5, 6]. ASE alone strongly inhibited the ir-
radiation-induced increases of MMP-1 in vitro (Figure 3(a)).
Moreover, rather than suppressing the activity of retinoids
in this model, ASE actually enhanced their ability to inhibit
MMP-1 expression (Figure 3(b)). Thus, ASE may not only
directly inhibit MMP-1 expression, but also indirectly pro-
motes the skin antiaging eﬀects, boosting of retinoid action.
Aﬀerent somatic nerves with unmyelinated (C-) or mye-
linated (Aδ-) ﬁbers innervate the skin, and they respond to
a range of chemicals and physiologic stimuli such as heat,
cold, nociception, and UV light, participating in cutaneous
inﬂammation. On stimulation, the nerves rapidly release
active neuropeptides such as CGRP, tachykinins, and vasoac-
tive intestinal peptide (VIP), then they act on target cells
resulting in erythema, edema, hyperthermia, and pruritus
associated with sensitive skin symptoms [49]. In the present
study, we measured CGRP expression level after capsaicin
treatment in neuronal cells [50] then identiﬁed whether ASE
works as a potential inhibitor of CGRP-induced neurogenic
inﬂammation. Capsaicin might trigger cytosolic Ca2+ inﬂux
through delta opioid receptor (DOR) activation in human
SK-N-BE(2) and SH-SY5Y neuroblastoma cells [51–53],
and elevated Ca2+ levels could induce CGRP release from
neuronal cells [54]. Our present results also revealed that
ASE decreased the release of CGRP from SK-N-BE(2) and
SH-SY5Y neuroblastoma cells following capsaicin treatment
in a dose-dependent manner (Table 1)[ 55]. This suggests
that ASE may reduce sensitive skin symptoms related to
cutaneous neurogenic inﬂammation.
5. Conclusions
We herein show that ASE contained echitamine and loganin
as its major compounds and could potentially be used as
an anti-irritation agent to counter unwanted skin symptoms
such as those induced by retinoid treatment. ASE not only
markedly decreased several components of retinoid-induced
dermatitis, it but also boosted the ability of retinoids to
inhibit MMP-1 protein expression, suggesting that it could
enhance the antiwrinkle eﬀects of retinoids. We are currently
examining the molecular basis for this enhancement eﬀect,
but the present study provides evidence suggesting that ASE
should be considered a good candidate for development as
ab i o l o g i c a l l ye ﬀective anti-irritation compound that is also
capable of conferring antiwrinkle eﬀects.
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